Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon’s 2006 Marketing Focus: Sparlon For ADHD, Nuvigil For Narcolepsy

Executive Summary

Cephalon will position its attention deficit hyperactivity disorder therapy Sparlon (modafinil) as a "non-traditional" stimulant for inattentive patients with mild-to-moderate hyperactivity

You may also be interested in...



Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says

Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23

Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says

Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23

Sparlon Skin Reaction Safety Study Is Unlikely To Erase Need For Black Box

Labeling for Sparlon for attention deficit/hyperactivity disorder will likely carry a black box warning for severe dermatological reactions even if Cephalon conducts an additional safety study to obtain approval

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel